Melittin: Bee Venom Peptide Shows Broad Anti-Viral Activity Against Multiple Viruses
Melittin, the main peptide in honeybee venom, has demonstrated antiviral activity against at least nine different viruses including HIV, influenza, and herpes simplex virus.
Quick Facts
What This Study Found
Melittin demonstrates antiviral activity against at least nine different viruses spanning multiple families, suggesting broad-spectrum potential as a venom-derived antiviral peptide.
Key Numbers
Active against 9+ viruses; properties: anti-cancer, anti-inflammatory, anti-diabetic, adjuvant; safety challenges significant
How They Did This
Narrative review synthesizing experimental studies on melittin antiviral activity conducted over several decades.
Why This Research Matters
Viral infections remain a leading cause of death globally, and drug resistance is growing. Natural venom peptides like melittin could offer new antiviral mechanisms that complement existing treatments.
The Bigger Picture
Melittin exemplifies how animal venom peptides — evolved for defense — may be repurposed as broad-spectrum antimicrobial and antiviral therapeutics, expanding the natural product drug pipeline.
What This Study Doesn't Tell Us
Most evidence is from in-vitro studies; melittin is cytotoxic at higher concentrations; safety profile for therapeutic use is unclear; molecular mechanisms remain poorly characterized.
Questions This Raises
- ?Can melittin be modified to retain antiviral activity while reducing its cytotoxicity?
- ?What are the specific molecular mechanisms behind melittin broad-spectrum antiviral action?
- ?Could nanoformulation delivery systems make melittin safe enough for clinical antiviral use?
Trust & Context
- Key Stat:
- 9+ viruses inhibited Melittin demonstrated antiviral activity across diverse viral families including HIV, influenza A, and HSV
- Evidence Grade:
- Broad observational evidence across many in-vitro studies, but lacks clinical trials or robust in-vivo data; safety profile is a major gap.
- Study Age:
- Published in 2020; interest in venom-derived antivirals has grown since the COVID-19 pandemic highlighted the need for broad-spectrum antiviral agents.
- Original Title:
- Melittin: a venom-derived peptide with promising anti-viral properties.
- Published In:
- European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 39(1), 5-17 (2020)
- Database ID:
- RPEP-04996
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can bee venom kill viruses?
Melittin, the main peptide in bee venom, has shown ability to inhibit at least nine different viruses in laboratory studies, though it has not yet been tested as a clinical antiviral drug.
Is melittin safe to use as medicine?
Melittin is cytotoxic at higher doses, which is a major challenge. Researchers are exploring modified versions and nanodelivery systems to make it safe for therapeutic use.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04996APA
Memariani, Hamed; Memariani, Mojtaba; Moravvej, Hamideh; Shahidi-Dadras, Mohammad. (2020). Melittin: a venom-derived peptide with promising anti-viral properties.. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 39(1), 5-17. https://doi.org/10.1007/s10096-019-03674-0
MLA
Memariani, Hamed, et al. "Melittin: a venom-derived peptide with promising anti-viral properties.." European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2020. https://doi.org/10.1007/s10096-019-03674-0
RethinkPeptides
RethinkPeptides Research Database. "Melittin: a venom-derived peptide with promising anti-viral ..." RPEP-04996. Retrieved from https://rethinkpeptides.com/research/memariani-2020-melittin-a-venomderived-peptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.